NetworkNewsBreaks – Predictive Oncology (NASDAQ:
Post# of 281
(Total Views: 184)
Posted On: 01/19/2021 4:54:24 PM
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common stock shares at $1.00 per share; the registered direct offering, priced at-the-market following Nasdaq rules, will result in gross proceeds of $2.2 million for the company. Predictive Oncology plans to use the net proceeds from the offering for working capital purposes. In addition, POAI agreed to issue unregistered warrants to the investors to purchase up to 1,100,000 additional shares of common stock. The company noted that the warrants have an exercise price equal to $1.00 per share and are exercisable upon issuance with an expiration date five and one-half years from the issuance date. POAI’s offering is expected to close on or about Jan. 21, 2021, pending customary closing conditions.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common stock shares at $1.00 per share; the registered direct offering, priced at-the-market following Nasdaq rules, will result in gross proceeds of $2.2 million for the company. Predictive Oncology plans to use the net proceeds from the offering for working capital purposes. In addition, POAI agreed to issue unregistered warrants to the investors to purchase up to 1,100,000 additional shares of common stock. The company noted that the warrants have an exercise price equal to $1.00 per share and are exercisable upon issuance with an expiration date five and one-half years from the issuance date. POAI’s offering is expected to close on or about Jan. 21, 2021, pending customary closing conditions.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼